Opening Hours : Monday to Friday - 9am to 5pm
  Contact : (03) 9871 4788

Daniel’s Current & Past Research

Dr van Langenberg’s current research projects (selected)

Project title: “De novo combination allopurinol-thiopurine vs standard thiopurine in inflammatory bowel disease patients escalating to immunomodulators: Randomized controlled trial (2014-)

Principal Investigator: DR van Langenberg (DvL)

Overall objective: To definitively assess whether de novo combination thiopurine-allopurinol is superior in terms of objective clinical outcomes (at week 26) compared with standard thiopurine monotherapy dosing at time of escalation to immunomodulator in IBD patients.

Project title: “The clinical utility/ application of anti TNF drug levels and antibodies  in the Australian setting”: 2013-current

Researchers: Dr Rimma Goldberg, Dr Greg Moore, Dr Sally Bell, Dr Daniel van Langenberg, Dr Lauren Beswick, Prof Peter Gibson.

Overall objective: To assess the clinical usefulness of these tests in routine clinical practice in order to optimize outcomes in IBD patients on anti-TNF therapies in Australia

Progress: Preliminary data analysis completed and presented at ECCO meeting Copenhagen February 2014

Project title: “Outcome and cost analysis of infliximab vs colectomy as salvage therapy for acute severe ulcerative colitis: A single, real world Australian centre experience” (2013-current)

Researchers: Dr Abhi Vasudevan, Dr Asiri Arachchi, Dr Daniel van Langenberg

Overall Objective: To assess patient/ disease outcomes including hospital-based costs in those patients who have received infliximab infusion(s), compared with those who received colectomy, as salvage therapy for acute severe colitis

Progress: Data collected and now analysis phase underway. To be presented at AGW 2014 (October)

Project title: “The Role of Serum Infliximab Levels in the Management of Patients with Acute Severe Ulcerative Colitis Treated with Infliximab”: (2014-current)

Principal Investigators: Dr Lauren Beswick, Dr Miles Sparrow, Dr Daniel van Langenberg, Prof Peter Gibson.

Overall objective: To assess the relationship between early infliximab drug levels and clinical response/ outcomes to salvage infliximab therapy for acute severe colitis

Progress: Ethics approval recently received, patient recruitment and testing underway

Project title: “Analysis of Whole-Genome Copy Number Variation in Crohn’s Disease Fistula Tissue”

Researchers: Dr Phillip Parker, A/Prof Aaron Russell (School of Exercise Science and Nutrition Deakin University) in collaboration with Dr D van Langenberg and Dr Patrick Hosking (Eastern Health) 2010-2014

Overall Objective: To assess the hypothesis that copy number variations and/or chromosomal instability are factors involved in the pathogenesis of fistulae in patients with Crohn’s disease

Progress: First phase completed, preliminary results submitted for publication.

Dr van Langenberg’s peer-reviewed publications as of 2014

DR van Langenberg, RB Gearry, M Ward, HL Wong, PR Gibson. The role of faecal lactoferrin in the evaluation of hospitalised patients with diarrhoea. Intern Med J 2010 Dec;40(12):819-27. 

JM Andrews, RE Mountfield, DR van Langenberg, PA Bampton, GJ Holtmann. Review: Unpromoted issues in inflammatory bowel disease (IBD) – opportunities to optimize care. Intern Med J 2010; 40: 173–182.

NY Zakary, DR van Langenberg, M Alshumrany, MN Schoeman. Acute haemorrhage from a Dieulafoy lesion within a gastric diverticulum managed endoscopically J Gastroenterol Hepatol. 2009 Dec;24(12):1891. 

DR van Langenberg, SJ Simon, G Holtmann, JM Andrews. The burden of inpatient costs in inflammatory bowel disease:  opportunities to optimize care. J Crohn Colitis 2010 Oct;4(4):413-21. 

DR van Langenberg, K Lange, DJ Hetzel, G Holtmann, JM Andrews. Adverse clinical phenotype in IBD: a cross sectional study identifying factors potentially amenable to change. J Gastroenterol Hepatol. 2010 Jul;25(7):1250-8.

DR van Langenberg, PR Gibson. Systematic Review: Fatigue in inflammatory bowel disease. Aliment Pharm Ther 2010; 32 (2): 131–143.

RV Bryant, DR van Langenberg, GJ Holtmann, JM Andrews. Functional gastrointestinal disorders in IBD patients: functional symptoms correlate with poorer health-related quality of life and increased psychological co-morbidity. J Gastroenterol Hepatol. 2011 May;26(5):916-23.

JM Andrews, RV Bryant, DR van Langenberg, GJ Holtmann. Are all symptoms in patients with IBD due to occult inflammation? Am J Gastroenterol 2010;105(12): 2703.

J. Gapasin, DR van Langenberg, G Holtmann, DJ Hetzel, JM  Andrews. Potentially avoidable surgery in IBD: what proportion of patients come to resection without optimal preoperative therapy? A guidelines-based audit. Intern Med J 2012; 42(5):e84-88

DR van Langenberg, G Morrison, A Foley, RJ Buttigieg, PR Gibson. Cytomegalovirus disease, haemophagocytic syndrome, immunosuppression in patients with IBD: ‘a cocktail best avoided, not stirred’. J Crohn Colitis 2011; 5(5): 469-472

VAH Phan, DR van Langenberg, R Grafton, JM Andrews. A dedicated inflammatory bowel disease service quantitatively and qualitatively improves outcomes in less than 18 months: a prospective cohort study in a large metropolitan centre. Front Gastroenterol ;3(3): 137-142

C Sack, VAH Phan, R Grafton, GJ Holtmann, DR van Langenberg, K Brett, M Clark, JM Andrews. A chronic care model significantly decreases costs and healthcare utilisation in patients with inflammatory bowel disease. J Crohn Colitis 2012; 6(3):302-310. 

DR van Langenberg, JM Andrews. Satisfaction with patient-doctor relationships in inflammatory bowel diseases: Examining patient-initiated change of specialist  World J Gastroenterol 2012; 18(18): 2212-2218

G Morrison, DR van Langenberg, SJ Gibson, PR Gibson. Chronic pain in inflammatory bowel disease: characteristics and associations in a hospital-based cohort.  Inflamm Bowel Dis 2013; 19(6): 1210-1217

L Prideaux, MA Kamm, P De Cruz, DR van Langenberg, SC Ng, I Dotan. Inflammatory Bowel Disease Serology in Asia and the West. World J Gastroenterol 2013 epub 10/6/2013

DR van Langenberg. Editorial: Maintaining muscle strength in Crohn’s disease: can a vitamin D daily keep muscle loss away? Dig Dis Sci 2013; 58(2): 293-295

DR van Langenberg, P Della Gatta, SA Warmington, DK Kidgell, PR Gibson, AP Russell. Objectively measured muscle fatigue in Crohn’s disease: Correlation with self-reported fatigue and associated factors for clinical application. J Crohn Colitis epub 11/7/2013

CK Yao, HL Tan, DR Van Langenberg, JS Barrett, PR Gibson, JG Muir. Dietary sorbitol and mannitol: food content and distinct absorption patterns between healthy individuals and patients with irritable bowel syndrome. J Hum Nutr Diet 2013 [ePub Aug 2013]

DR van Langenberg, P Della Gatta, B Hill, E Zacharewicz, PR Gibson, AP Russell. Delving into disability in Crohn’s disease: dysregulation of molecular pathways may explain skeletal muscle loss in Crohn’s disease. J Crohn Colitis 2013 [ePub Nov 2013]

L Prideaux, S Kang, J Wagner, M Buckley, JE Mahar, P De Cruz, Z Wen, L Chen, B Xia, DR van Langenberg, T Lockett, SC Ng, JJY Sung, P Desmond, C McSweeney, M Morrison, CD Kirkwood, MA Kamm. Impact of Ethnicity, Geography and Disease on the Microbiota in Health and Inflammatory Bowel Disease. Inflamm Bowel Dis 2013 [in press]

A Vasuvedan, A Arachchi, DR van Langenberg.Assessing patient satisfaction in inflammatory bowel disease using the QUOTE-IBD survey: A small step for clinicians, a potentially large step for improving quality of care.” J Crohn Colitis [ePub March 2013]

DR van Langenberg, PR Gibson. Factors associated with physical and cognitive fatigue in patients with Crohn’s disease: a cross-sectional and longitudinal study. Inflamm Bowel Dis 2013 [ePub Nov 2013]

PD Parker, DR van Langenberg, P Hosking, AP Russell. Analysis of Whole-Genome Copy-Number Variation in Crohn’s Disease Fistula Tissue. J Crohn Colitis 2014 [submitted for publication]

SL James, DR van Langenberg, JJ Muir, PR Gibson.Characterisation of Ulcerative colitis-associated constipation syndrome (Proximal constipation). J Crohn Colitis 2014 [submitted for publication]

Other publications:

DR van Langenberg. “Demystifying Fatigue in Inflammatory Bowel Disease” [article]. Inside Insight (magazine of the Crohn’s and Colitis Association Australia) Winter Edition, 2010. 

JM Andrews, R Grafton, DR van Langenberg, VA Phan, DJ Hetzel, MN Schoeman. “The Introduction of a formal IBD Service with an Extended Roles IBD Nurse Improves Outcomes for Patients and Saves Money.” Inside Insight (magazine of the Crohn’s and Colitis Association Australia) Spring Edition, 2010.

DR van Langenberg. Muscle dysfunction & Crohn’s disease: an unheralded problem. Inside Insight (magazine of the Crohns and Colitis Association Australia) Autumn Edition, 2012

DR van Langenberg. Mucosal healing in Crohn’s disease: a new goal, a new paradigm (Gastrocentral educational website, Janssen Pty Ltd 2013).

DR van Langenberg, A MacFarlane. Case report of Mezavant use in IBD patient as educational resource, [in press] 2014).

DR van Langenberg. Fatigue in inflammatory bowel disease. Chapter 15 in “A biopsychosocial approach to management of IBD”, Eds Knowles & Mikocka-Walus, Routledge, 2014 [in press]